SG33647G - Steroidal 17alpha-silyl ethers and process to corticoids and progesterones - Google Patents

Steroidal 17alpha-silyl ethers and process to corticoids and progesterones

Info

Publication number
SG33647G
SG33647G SG1995905980A SG1995905980A SG33647G SG 33647 G SG33647 G SG 33647G SG 1995905980 A SG1995905980 A SG 1995905980A SG 1995905980 A SG1995905980 A SG 1995905980A SG 33647 G SG33647 G SG 33647G
Authority
SG
Singapore
Prior art keywords
corticoids
progesterones
17alpha
steroidal
silyl ethers
Prior art date
Application number
SG1995905980A
Other languages
English (en)
Inventor
Douglas Alan Livingston
Bruce Allen Pearlman
Scott Denmark
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of SG33647G publication Critical patent/SG33647G/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0015—Oxiranes at position 9(11)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
    • C07J5/0076—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG1995905980A 1986-11-05 1987-11-02 Steroidal 17alpha-silyl ethers and process to corticoids and progesterones SG33647G (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92763386A 1986-11-05 1986-11-05
US2045787A 1987-03-02 1987-03-02

Publications (1)

Publication Number Publication Date
SG33647G true SG33647G (en) 1995-09-01

Family

ID=26693463

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1995905980A SG33647G (en) 1986-11-05 1987-11-02 Steroidal 17alpha-silyl ethers and process to corticoids and progesterones

Country Status (15)

Country Link
US (1) US4977255A (ko)
EP (2) EP0334875A1 (ko)
JP (2) JP2549721B2 (ko)
KR (1) KR960006394B1 (ko)
AT (1) ATE75484T1 (ko)
AU (1) AU8335587A (ko)
CA (1) CA1317283C (ko)
DE (1) DE3778651D1 (ko)
ES (1) ES2039249T3 (ko)
GR (1) GR3005079T3 (ko)
HK (1) HK69595A (ko)
HU (2) HU209783B (ko)
PT (1) PT86083B (ko)
SG (1) SG33647G (ko)
WO (1) WO1988003534A1 (ko)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69132048T2 (de) * 1990-06-11 2000-07-13 Alcon Lab Inc N D Ges D Staate Verwendung von Steroiden zur Inhibierung von Angiogenesis
US5972922A (en) * 1990-06-11 1999-10-26 Alcon Laboratories, Inc. Steroids which inhibit angiogenesis
CN1147816A (zh) * 1994-05-09 1997-04-16 法玛西雅厄普约翰公司 17β-氰基-3-乙氧基-17α-羟基-6-甲基雄甾-3，5，9(11)-三烯的合成
US5929262A (en) * 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
WO2001074840A2 (en) 2000-03-17 2001-10-11 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregna 21-substituted 19-norpregnadienedione as antiprogestational agents
KR100694079B1 (ko) 2005-01-08 2007-03-12 학교법인 대양학원 유무선 통합 네트워크에서 ｐ２ｐ 서비스를 위한 데이터다운로드 방법 및 그 노드
DK2444092T3 (en) * 2008-05-28 2015-09-28 Reveragen Biopharma Inc Non-hormonal steroidmodulatorer of NF-? B for the treatment of disease
WO2011127048A2 (en) 2010-04-05 2011-10-13 Validus Biopharma NON-HORMONAL STEROID MODULATORS OF NF-ĸB FOR TREATMENT OF DISEASE
CN103601786A (zh) * 2013-11-22 2014-02-26 湖南新合新生物医药有限公司 甲基泼尼松龙关键中间体的制备方法
CN103833814A (zh) * 2014-03-06 2014-06-04 浙江仙居君业药业有限公司 17羟基-孕甾-4-烯-3,20-二酮-21-醋酸酯的制备方法
CN103910775A (zh) * 2014-03-31 2014-07-09 仙居县圃瑞药业有限公司 17α-羟基黄体酮的合成方法
CN104311619A (zh) * 2014-07-08 2015-01-28 仙居县圃瑞药业有限公司 一种采用串联法合成黄体酮的方法
CN104311625B (zh) * 2014-11-06 2016-03-23 江西赣亮医药原料有限公司 一种醋酸氟轻松中间体的制备方法
US10799514B2 (en) 2015-06-29 2020-10-13 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-kappa beta for treatment of disease
CN105801651B (zh) * 2016-04-19 2018-03-06 浙江仙居君业药业有限公司 一种17α‑羟基黄体酮的合成方法
CN109517020B (zh) * 2018-11-22 2020-12-15 湖南原野医药有限公司 Delta-9,11-羟基黄体酮的合成方法
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions
CN117257775A (zh) * 2023-11-01 2023-12-22 南京羚诺生物医药技术研究院有限公司 一种子宫内膜异位症用口溶膜制剂及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2082129A5 (ko) * 1970-03-04 1971-12-10 Roussel Uclaf
SE387854B (sv) * 1973-11-21 1976-09-20 O L Lindblad Paverkningsorgan, foretredesvis avsett att anvendas i samband med fordonsekerhetsselar
US4081537A (en) * 1975-10-10 1978-03-28 Schering Aktiengesellschaft Δ15 -Steroids and pharmaceutical compositions thereof
JPS5762296A (en) * 1980-10-01 1982-04-15 Mitsubishi Chem Ind Ltd Preparation of 17alpha-hydroxyprogesterone derivative
JPS5762298A (en) * 1980-10-01 1982-04-15 Mitsubishi Chem Ind Ltd Preparation of 17alpha-cyanosteroid
JPS5762299A (en) * 1980-10-01 1982-04-15 Mitsubishi Chem Ind Ltd Preparation of 17alpha-cyanosteroid
US4500461A (en) * 1984-02-03 1985-02-19 The Upjohn Company Cyanohydrin process
US4548748A (en) * 1984-02-03 1985-10-22 The Upjohn Company Cyanohydrin process
US4585590A (en) * 1984-02-03 1986-04-29 The Upjohn Company Cyanohydrin process
DE3585547D1 (de) * 1984-02-03 1992-04-16 Upjohn Co Steroide mit einer enamid- oder enimidgruppe sowie ihre herstellung.
DE3427486A1 (de) * 1984-07-23 1986-01-30 Schering AG, Berlin und Bergkamen, 1000 Berlin Verfahren zur herstellung von 6(alpha)-methylsteroiden

Also Published As

Publication number Publication date
HU209783B (en) 1994-10-28
JPH07278183A (ja) 1995-10-24
ES2039249T3 (es) 1993-09-16
PT86083B (pt) 1990-11-20
DE3778651D1 (de) 1992-06-04
HUT65138A (en) 1994-04-28
ATE75484T1 (de) 1992-05-15
JPH02500911A (ja) 1990-03-29
CA1317283C (en) 1993-05-04
HU892262D0 (en) 1992-09-28
GR3005079T3 (ko) 1993-05-24
EP0268400A1 (en) 1988-05-25
JP2515967B2 (ja) 1996-07-10
HK69595A (en) 1995-05-12
US4977255A (en) 1990-12-11
KR890700130A (ko) 1989-03-10
JP2549721B2 (ja) 1996-10-30
EP0268400B1 (en) 1992-04-29
EP0334875A1 (en) 1989-10-04
WO1988003534A1 (en) 1988-05-19
AU8335587A (en) 1988-06-01
PT86083A (en) 1987-12-01
KR960006394B1 (ko) 1996-05-15

Similar Documents

Publication Publication Date Title
PT86083A (en) Steroidal 17 alpha-silyl ethers and process to corticoids and progesterones
AU4970479A (en) Improvements relating to the treatment of flat glass
AU508224B2 (en) 9 21-dihalogeno-11 17 -dihydroxy-6 -fluro-16-methyl-pregna-1,4-diene-3,20-diones
IL57596A0 (en) Process the purification and concentration of urokinase
HUT45399A (en) Production of seditive compositions by applying medetomidine
DE2962925D1 (en) Process for the preparation of pure potassium ribonate and pure ribonolactone
PT78030A (en) Process for the preparation of an ointment based in 17-alpha-propyloxi-11beta-hydroxi-4-pregnene-3,20-dione
AU591305B2 (en) Improved process for preparing 5,6-substitued-2,4- quinazolinediamines and novel intermediates
AU8225187A (en) Reduced-stability alpha-amylase and process for its production
AU596688B2 (en) Process for the production of low carbon silicon
DE2960478D1 (en) Coke for use in the production of gray iron; method of producing said coke and method of producing gray iron by using said coke
DE2966657D1 (en) Process for dehydroxylation of 13-hydroxygibberellins and intermediates useful in the process
AU521461B2 (en) Process for beneficiation of titanium ores
ZA793619B (en) Process for dehydroxylation of 13-hydroxygibberellins and intermediates useful in the process
AP9600790A0 (en) Process for preparation of substituted steroidal dienes and novel intermediates used in said process.
EP0104054A3 (en) 16-methylene-steroids and their preparation
KR790000589B1 (en) Method for producing 6l-fluoro-17,21-dehydroxy-16b-methylpregna-4,9(11)diene-3,20-dione17,21-diacetate
AU2910589A (en) Diagnostic method for primary biliary cirrhosis and antibodies suitable to be used in the method
PT79617A (en) Process for the preparation of an arginine based pharmaceuticalomposition useful in the teraphy of hipotrophic conditions
JPS55118397A (en) Production of androstane and pregnane type 199 hydroxy steroid
DE3160507D1 (en) Process for the preparation of 3,20-dioxo-pregn-4-ene and/or 3,20-dioxo-pregna-1,4-diene
ES8507155A3 (es) Metodo para la obtencion de esteroides de la serie de prednisolona
ZA79318B (en) New steroids of the pregnane series substituted in the 17-position,and their manufacture and use
JPS5426212A (en) Iron ore reducing method
EP0301102A4 (en) NOVEL 7-g (b) -HYDROXY-4-PREGNENE-3,20-DIONE DERIVATIVES AND PREPARATION METHODS.